West German Study Group

This study is for people with low-risk, early-stage triple-negative breast cancer. It compares two treatments: one drug alone versus that drug plus an immunotherapy. The goal is to see which approach leads to a complete disappearance of cancer before surgery. About 348 participan…

This phase 3 study tests whether adding capivasertib to standard hormone therapy helps people with HR+/HER2- advanced breast cancer stay on treatment longer and maintain quality of life. About 250 adults whose cancer worsened after prior hormone therapy will take capivasertib plu…

This study tests if a new hormone therapy called elacestrant, taken for 5 years, can better prevent breast cancer from coming back compared to standard hormone therapy in people with high-risk HR+/HER2- early breast cancer. About 1,520 participants will receive either elacestrant…

This study follows about 1,470 premenopausal women with a common type of early breast cancer to see how well hormone therapy (with or without ovarian suppression) works compared to chemotherapy followed by hormone therapy. Participants are chosen based on a genetic test (MammaPri…